| Prev Close | 3.69 |
| Day Low/High | 3.63 / 3.74 |
| 52 Wk Low/High | 2.38 / 5.57 |
| Avg Volume | 1.97M |
| Exchange | NASDAQ |
| Shares Outstanding | 145.02M |
| Market Cap | 535.13M |
| EPS | -0.70 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Array BioPharma (ARRY) Stock Advances, Price Target Raised at Jefferies
Jefferies upped its price target on Array BioPharma (ARRY) to $7 earlier today.
Short Interest Moves 13.5% Lower For ARRY
The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 2,190,797 share decrease in total short interest for Array BioPharma Inc. , to 14,071,789, a decrease of 13.47% since 07/29/2016.
Interesting ARRY Put And Call Options For October 21st
Investors in Array BioPharma Inc. saw new options begin trading today, for the October 21st expiration.
Array BioPharma (ARRY) Stock Drops on Failed Lung Cancer Drug Trial
Array BioPharma (ARRY) stock was tumbling in late-afternoon trading after the company's cancer drug trial failed to meet its primary endpoint.
Array BioPharma (ARRY) Trading With Heavy Volume Before Market Open
Trade-Ideas LLC identified Array BioPharma (ARRY) as a pre-market mover with heavy volume candidate
5 Best-Positioned Biotech Stocks on Brexit Volatility
Biotech stocks remain pressured following the recent Brexit vote, which will make investing in these already highly volatile stocks even trickier. But there are opportunities too.
Array BioPharma (ARRY) Stock: Weak On High Volume Today
Trade-Ideas LLC identified Array BioPharma (ARRY) as a weak on high relative volume candidate
First Week of December 16th Options Trading For Array BioPharma (ARRY)
Investors in Array BioPharma Inc. saw new options begin trading this week, for the December 16th expiration.
Loxo Cancer Drug Targets Gene Mutation With Durable Responses in Early Study
Six patients, all with TRK fusion cancers unresponsive to current therapies, reported tumor shrinkage following treatment with Loxo's drug LOXO-101.
Array BioPharma (ARRY) Is Today's Strong On High Volume Stock
Trade-Ideas LLC identified Array BioPharma (ARRY) as a strong on high relative volume candidate
Array BioPharma (ARRY) Is Strong On High Volume Today
Trade-Ideas LLC identified Array BioPharma (ARRY) as a strong on high relative volume candidate
Array BioPharma (ARRY) Is Today's Strong On High Volume Stock
Trade-Ideas LLC identified Array BioPharma (ARRY) as a strong on high relative volume candidate
Commit To Buy Array BioPharma At $2, Earn 25% Using Options
Investors eyeing a purchase of Array BioPharma Inc. stock, but tentative about paying the going market price of $3.19/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Short Interest In Array BioPharma Moves 10.3% Lower
The most recent short interest data has been released by the NASDAQ for the 12/31/2015 settlement date, which shows a 2,674,046 share decrease in total short interest for Array BioPharma Inc. , to 23,339,973, a decrease of 10.28% since 12/15/2015.
5 Stocks Insiders Love Right Now
Insiders at these companies have been scooping up shares of their own stock lately.
QIAGEN Reaches Milestone With Portfolio Of Master Collaboration Agreements For Pharma Companion Diagnostics
Record number of new projects involves start of new master collaboration with Array BioPharma
Array Biopharma (ARRY) Stock Spikes on Successful Drug Study
Array Biopharma (ARRY) stock is skyrocketing in afternoon trading on Wednesday following a successful late-stage study for its skin cancer drug.
Array BioPharma (ARRY) Moving On Heavy Pre-Market Trading
Trade-Ideas LLC identified Array BioPharma (ARRY) as a pre-market mover with heavy volume candidate
Array BioPharma (ARRY): Today's Weak On High Volume Stock
Trade-Ideas LLC identified Array BioPharma (ARRY) as a weak on high relative volume candidate
Array BioPharma (ARRY) Strong On High Relative Volume Today
Trade-Ideas LLC identified Array BioPharma (ARRY) as a strong on high relative volume candidate
Trade-Ideas: Array BioPharma (ARRY) Is Today's Weak On High Relative Volume Stock
Trade-Ideas LLC identified Array BioPharma (ARRY) as a weak on high relative volume candidate
Array BioPharma Enters Oversold Territory (ARRY)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
First Week of ARRY June 2016 Options Trading
Investors in Array BioPharma Inc. saw new options begin trading this week, for the June 2016 expiration.
5 Stocks Insiders Love Right Now
Insiders at these companies have been scooping up shares of their own stock lately.
Array BioPharma Becomes Oversold (ARRY)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
